Loss of TP53, in combination with activating mutations within members of the MAPK pathway, exemplified by alterations in KRAS, is the commonly observed driver of human NSCLC (Figure 1A and Supplementary Figure 1A). Here, KRAS is linked to non-small cell lung carcinoma.